Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Rises 9.69% Today

Fredun Pharmaceuticals Ltd. Share Price Today rose to Rs 1,528.80, up 9.69%, taking the Healthcare small-cap company’s market capitalisation to Rs 2,110.42 crore.

Fredun Pharmaceuticals Ltd. Share Price moved sharply higher on 13 August 2026, with the stock trading at Rs 1,528.80, up Rs 135.10 or 9.69% from the previous close of Rs 1,393.70. At this level, the company’s market capitalisation stood at Rs 2,110.42 crore, placing it in the Small Cap category. The move also qualified under the workflow’s price rise threshold for its market-cap bracket, making Fredun Pharmaceuticals Ltd. Share Price one of the notable Stocks in News during today’s session.

From a search and market perspective, this matters because Fredun Pharmaceuticals Ltd. Share Price Today combined a strong single-day gain with a decisive move from the opening level of Rs 1,401.00 to an intraday high of Rs 1,530.50. That places the stock among the Top Gainers Today within its listed universe. The supplied data confirms the price event, though it does not establish a company-specific catalyst for why the stock is rising today.

What the verified figures do show is that Fredun Pharmaceuticals Ltd. Share Price has attracted attention in the Healthcare sector, specifically within Pharmaceuticals & Drugs. Investors tracking Fredun Pharmaceuticals Ltd. Stock News are also likely to note its valuation profile, with a P/E ratio of 52.60 and P/B ratio of 7.86, alongside ROE of 11.42% and ROCE of 13.15%. As Univest reviews today’s move, the key things to monitor next are whether price strength sustains, how valuation compares with industry benchmarks, and where the stock stands against direct listed peers.

Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,528.8
Previous Close	Rs 1,393.7
Today's Change	+Rs 135.1 (+9.69%)
Day Open	Rs 1,401
Day High	Rs 1,530.5
Day Low	Rs 1,401
Current Volume (BSE)	32,243
BSE Traded Volume	32,243
Combined NSE + BSE Volume	32,243
Turnover	Rs 4.93 crore
Market Capitalisation	Rs 2,110.42 crore
Market Cap Category	Small Cap

Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,528.8. versus the previous close of Rs 1,393.7, a rise of 9.69%. The stock opened at Rs 1,401, reached Rs 1,530.5, touched Rs 1,401. Reported volume was 32,243.

Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,110.42 crore
P/E Ratio	52.6x
P/B Ratio	7.86x
ROE	11.42%
ROCE	13.15%
EPS	Rs 26.5
Book Value Per Share	Rs 177.38
Dividend Yield	0.02%

Fredun Pharmaceuticals Ltd. was valued at a P/E ratio of 52.6x, a P/B ratio of 7.86x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 11.42% and ROCE of 13.15%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 26.5, book value per share of Rs 177.38, dividend yield of 0.02%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Fredun Pharmaceuticals Ltd. Share Price is now being judged against a market capitalisation of Rs 2,110.42 crore and a valuation multiple of 52.60 times earnings. In pure valuation terms, that means the market is assigning a relatively rich earnings multiple compared with many listed businesses, though valuation language is most useful when placed against an industry benchmark. The company’s P/B ratio of 7.86 also indicates that the stock is trading at a sizeable premium to its accounting book value base.

The profitability picture is more balanced. Return on equity stands at 11.42%, while return on capital employed is 13.15%. These figures suggest the business is generating double-digit returns on shareholder funds and capital employed, but not at the very top end of the Pharmaceuticals & Drugs space. EPS is Rs 26.50, which shows the earnings attributable to each share based on the supplied data. Book value per share is Rs 177.38, which gives an accounting net worth reference against the current share price. Dividend yield is 0.02, a very small historical/current payout relative to the current market price.

Looking at how investors may interpret Fredun Pharmaceuticals Ltd. Fundamental Analysis, the key contrast is between profitability that is respectable and valuation that is elevated versus broad industry medians. That does not by itself make the stock overvalued or undervalued; it simply frames the debate around how much current performance the market is already pricing in. Univest notes that Fredun Pharmaceuticals Ltd. Stock Analysis today is less about a low-multiple rerating story and more about whether investors are willing to sustain interest in a business already trading above several benchmark valuation reference points.

For those tracking Fredun Pharmaceuticals Ltd. Earnings, the supplied fundamentals provide a concise snapshot: a small-cap healthcare company with positive return ratios, modest dividend yield, and a share price that stands well above its book value per share. That combination can keep a stock in focus when price momentum improves, which is why ownership structure would normally be worth watching alongside fundamentals. In this case, the stronger comparative lens comes from industry and peer data.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	52.6x
Benchmark Median P/E	25.27x
Benchmark Average P/E	69.01x
Benchmark P/E Range	3.44x to 3,374.81x
Company P/B Ratio	7.86x
Benchmark Median P/B	1.82x
Company ROE	11.42%
Benchmark Median ROE	10.49%
Company ROCE	13.15%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 2,110.42 crore
Benchmark Median Market Cap	Rs 147.59 crore

Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 52.6x, which is above the benchmark median of 25.27x, a difference of +108.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 11.42%, which is above the benchmark median of 10.49%, a difference of +8.87%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 13.15%, which is above the benchmark median of 12.97%, a difference of +1.39%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Fredun Pharmaceuticals Ltd. Share Price is moving within the Healthcare sector and, more specifically, the Pharmaceuticals & Drugs industry. The most useful benchmark here is the supplied same-industry comparison set covering 136 companies. That makes today’s Fredun Pharmaceuticals Ltd. Stock News more meaningful because the stock can be judged against a large and relevant listed universe rather than in isolation.

The headline sector comparison is valuation. Fredun Pharmaceuticals Ltd. Share Price carries a company P/E of 52.60. Within the same industry benchmark, the median P/E is 25.27, the average is 69.01, the minimum is 3.44 and the maximum is 3,374.81, based on 103 companies with P/E data. This means the stock is trading above the median but below the average, suggesting that while it is not cheap against the centre of the peer group, it is also not near the most stretched valuation readings in the industry distribution.

On price-to-book, the company’s P/B ratio of 7.86 is notably above the industry median of 1.82 and average of 2.44, across 135 companies. That places the stock at a premium to much of the same-industry pack on balance-sheet valuation. On profitability, ROE of 11.42% is above the industry median of 10.49% and above the average of 8.09%. ROCE of 13.15% is slightly above the median of 12.97% but below the average of 15.63%.

Size is another point of context. At Rs 2,110.42 crore, Fredun Pharmaceuticals Ltd. Market Cap sits far above the industry median market cap of Rs 147.59 crore and above the average of Rs 490.67 crore, while still below the benchmark maximum of Rs 3,027.48 crore. Univest therefore sees Fredun Pharmaceuticals Ltd. Share Price Today as a move in a relatively larger small-cap pharma name that is valued at a premium on P/B, above the median on P/E, and posting return ratios that are decent rather than extreme.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,027.48	0	0.77	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,958.04	68.39	10.82	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.2	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,559.74	171.25	3.13	13.9	12.97
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,474.06	44.25	1.76	-0.78	8.31

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 52.6x compared with the displayed peer median of 44.25x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.42% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 13.15% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,110.42 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Fredun Pharmaceuticals Ltd. Share Price can be assessed more closely by comparing it with nearby listed peers in the Pharmaceuticals & Drugs space. On market capitalisation, the company at Rs 2,110.42 crore sits just below Hester Biosciences Ltd. at Rs 2,112.08 crore, Sakar Healthcare Ltd. at Rs 2,122.09 crore and NGL Fine-Chem Ltd. at Rs 2,137.26 crore. It remains smaller than Solara Active Pharma Sciences Ltd. at Rs 2,455.60 crore, Panacea Biotec Ltd. at Rs 2,466.57 crore and Beta Drugs Ltd. at Rs 2,958.04 crore, but still belongs to the higher end of this small-cap comparison band.

In valuation terms, Fredun Pharmaceuticals Ltd. Share Price is on 52.60 times earnings. That is higher than Ind-Swift Laboratories Ltd. at 44.25 and NGL Fine-Chem Ltd. at 43.80, but lower than Beta Drugs Ltd. at 68.39 and far below Sai Parenteral’s Ltd. at 171.25. Sakar Healthcare Ltd. is close at 57.68, placing Fredun broadly in the middle-to-upper part of the available peer P/E range.

On profitability, ROE of 11.42% is ahead of Dishman Carbogen Amcis Ltd. at -2.89, Ind-Swift Laboratories Ltd. at -0.78 and Panacea Biotec Ltd. at 0, but below Beta Drugs Ltd. at 18.65, Hikal Ltd. at 15.22, Solara Active Pharma Sciences Ltd. at 17.23, NGL Fine-Chem Ltd. at 27.90 and Hester Biosciences Ltd. at 16.17. ROCE of 13.15% is almost identical to Sakar Healthcare Ltd. at 13.16 and above Panacea Biotec Ltd. at 5.36, Ind-Swift Laboratories Ltd. at 8.31 and Dishman Carbogen Amcis Ltd. at -0.26, but below NGL Fine-Chem Ltd. at 33.91 and Beta Drugs Ltd. at 22.17.

The P/B ratio of 7.86 is above Hikal Ltd. at 2.20, Ind-Swift Laboratories Ltd. at 1.76, Solara Active Pharma Sciences Ltd. at 1.91 and Hester Biosciences Ltd. at 4.59, but below Beta Drugs Ltd. at 10.82 and Panacea Biotec Ltd. at 8.59. Univest therefore reads Fredun Pharmaceuticals Ltd. Share Price as a stock priced at a premium to many peers on book value, with profitability that is positive and competitive, though not the strongest in the group.

Why Investors Are Watching Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. Share Price is being watched because today’s move was large enough to place the stock in the top gainer conversation within its category, while its valuation and peer metrics offer enough context to make the move analytically relevant. In short, the price action is strong, the business sits in a tracked pharma industry cohort, and the stock’s premium multiples make follow-through worth monitoring.

• Verified price action: the stock rose 9.69% to Rs 1,528.80 from Rs 1,393.70, after opening at Rs 1,401.00 and touching Rs 1,530.50.
• Trading participation: total BSE volume stood at 32,243 shares with turnover of Rs 4.93 crore.
• Fundamental context: P/E is 52.60, P/B is 7.86, ROE is 11.42%, ROCE is 13.15%, EPS is Rs 26.50 and book value is Rs 177.38.
• Sector positioning: P/E is above the industry median of 25.27, while ROE and ROCE sit around or above industry medians.
• Peer positioning: the company’s market cap is close to NGL Fine-Chem, Sakar Healthcare and Hester Biosciences.

What investors may monitor next is whether Fredun Pharmaceuticals Ltd. Share Price continues to hold near today’s upper range, and whether market attention remains anchored in valuation and relative profitability rather than just a single-session move. Univest also sees relevance in how the stock continues to compare with similarly sized pharma names in the same industry group.

About Fredun Pharmaceuticals Ltd.

Fredun Pharmaceuticals Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. That places the company in one of the most closely tracked areas of the Indian stock market, where investors often compare businesses on valuation, profitability, market capitalisation and relative scale within listed healthcare names.

Based on the supplied company context, the clearest way to understand Fredun Pharmaceuticals Ltd. is through its industry placement rather than broad market labels. It is a pharmaceutical business competing in a listed same-industry benchmark that includes 136 companies. Within that comparison set, Fredun Pharmaceuticals Ltd. Market Cap of Rs 2,110.42 crore makes it materially larger than the median company size of Rs 147.59 crore and above the average of Rs 490.67 crore. That gives the company a more visible position inside the small-cap pharma segment.

For readers searching Fredun Pharmaceuticals Ltd. Company News, Fredun Pharmaceuticals Ltd. Share News or Fredun Pharmaceuticals Ltd. Latest News, today’s relevance comes from the combination of business category and market behaviour: a Healthcare stock, inside Pharmaceuticals & Drugs, showing a notable single-day share price gain while trading on valuation multiples that are above several benchmark reference points. Univest therefore sees the company as a useful case study in how sector context and stock-specific price action intersect in the Indian Stock Market.

Track Fredun Pharmaceuticals Ltd. Share Price on Univest

Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Fredun Pharmaceuticals Ltd. Share Price can use Univest to track live share price moves, day change, market capitalisation, 52-week levels, valuation ratios and company-level market insights in one place. Fredun Pharmaceuticals Ltd. Share Price Today has already drawn attention because of its 9.69% gain, and platforms that organise price, sector and peer context can help users interpret such moves more efficiently.

On Univest, users can track Fredun Pharmaceuticals Ltd. Share Price Live alongside metrics such as P/E ratio, P/B ratio, ROE, ROCE, EPS, book value, dividend yield and peer comparison. That makes it easier to connect Stock Updates and Market News with the underlying numbers without turning a short-term move into an unsupported conclusion.

Frequently Asked Questions

What is Fredun Pharmaceuticals Ltd. Share Price Today?

Ans. Fredun Pharmaceuticals Ltd. Share Price Today was Rs 1,528.80 at the time of the event capture. The stock was up Rs 135.10 from the previous close of Rs 1,393.70, translating into a 9.69% single-day gain.

Why is Fredun Pharmaceuticals Ltd. Share Price rising today?

Ans. The supplied data confirms that Fredun Pharmaceuticals Ltd. Share Price rose 9.69% today and cleared the applicable price-rise threshold for its Small Cap category. The figures establish the move, though they do not identify a company-specific catalyst.

What were the day’s high, low and opening levels for Fredun Pharmaceuticals Ltd.?

Ans. Fredun Pharmaceuticals Ltd. opened at Rs 1,401.00, which was also the day’s low, and later touched an intraday high of Rs 1,530.50. That shows the stock strengthened through the session after opening above the previous close.

What is the market capitalisation of Fredun Pharmaceuticals Ltd.?

Ans. Fredun Pharmaceuticals Ltd. had a market capitalisation of Rs 2,110.42 crore in the supplied data. That places it in the Small Cap category and well above the Pharmaceuticals & Drugs industry median market capitalisation of Rs 147.59 crore.

How much volume was traded in Fredun Pharmaceuticals Ltd. today?

Ans. Total traded volume in Fredun Pharmaceuticals Ltd. stood at 32,243 shares on BSE, with turnover of Rs 4.93 crore. This indicates that the day’s price rise was accompanied by measurable market participation rather than an isolated trade print.

Is Fredun Pharmaceuticals Ltd. expensive compared with its industry P/E?

Ans. Fredun Pharmaceuticals Ltd. trades at a P/E of 52.60. That is above the same-industry median P/E of 25.27 but below the average of 69.01, placing the stock above the industry midpoint without being near the highest observed valuation.

How does Fredun Pharmaceuticals Ltd. compare on P/B ratio?

Ans. The company’s P/B ratio is 7.86, versus the industry median of 1.82 and average of 2.44. This means Fredun Pharmaceuticals Ltd. Share Price is trading at a clear premium to much of the Pharmaceuticals & Drugs peer universe on book.

What do the profitability ratios of Fredun Pharmaceuticals Ltd. show?

Ans. Fredun Pharmaceuticals Ltd. reported ROE of 11.42% and ROCE of 13.15% in the supplied dataset. ROE is above the industry median of 10.49%, while ROCE is marginally above the median of 12.97%.

What are the EPS, book value and dividend yield of Fredun Pharmaceuticals Ltd.?

Ans. Fredun Pharmaceuticals Ltd. has EPS of Rs 26.50, book value per share of Rs 177.38 and dividend yield of 0.02. These figures provide context on earnings per share, accounting net worth and historical/current payout relative to price.

Which sector and industry does Fredun Pharmaceuticals Ltd. belong to?

Ans. Fredun Pharmaceuticals Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark compares it with 136 same-industry companies, helping investors evaluate valuation, profitability and market-cap positioning within a relevant peer set.